Galenicum
St. Gabriel, 50, Esplugues de Llobregat, Barcelona, 08950, Spain
Overview
Galenicum engages in research and development, regulatory affairs, manufacturing, and supply of a range of medicines. They develop affordable products in a range of technologies, from injectables to oral solid forms and nasal sprays. Their approach to every development is a mixture of applying QbD standards.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Pharmaceutical
Investment portfolio
- AzureBio
Participated · Equity · May 2011
AzureBio is a Tres Cantos (Madrid), Spain–based biotechnology company specializing in new stabilization technologies for drugs and biomaterials. The company is developing “Injectable Needles,” a biodegradable solid-needle system for subcutaneous administration designed to replace conventional needles and avoid cold storage, reconstitution and the need for trained personnel in low-resource settings. It is also developing “Synthetic Bone,” a synthetic phosphate and silicate matrix for bone regeneration. AzureBio offers design services to third parties for administration of active ingredients and stabilization of reagents used in diagnosis and treatment. The company received an €800k equity financing from a group of investors including Fitalent, the “Real de Vellón” fund managed by Clave Mayor, Geiser Pharma and Galenicum.
Team
No current team members are available.